vs
CATALYST PHARMACEUTICALS, INC.（CPRX）与WSFS FINANCIAL CORP（WSFS）财务数据对比。点击上方公司名可切换其他公司
WSFS FINANCIAL CORP的季度营收约是CATALYST PHARMACEUTICALS, INC.的1.8倍（$275.3M vs $152.6M），CATALYST PHARMACEUTICALS, INC.净利率更高（34.5% vs 31.5%，领先3.0%），CATALYST PHARMACEUTICALS, INC.同比增速更快（7.6% vs 7.5%），过去两年CATALYST PHARMACEUTICALS, INC.的营收复合增速更高（24.5% vs 1.7%）
Catalyst Pharmaceuticals是一家总部位于美国佛罗里达州科勒尔盖布尔斯的生物制药企业，专注于罕见病药物研发。核心产品包括用于治疗兰伯特-伊顿肌无力综合征（LEMS）的氨吡啶磷酸盐，商品名为Firdapse。该药物2018年11月获FDA批准，除原有成人适应症外，还可用于6岁及以上的LEMS儿童患者。
WSFS金融集团是一家金融服务企业，核心子公司WSFS银行是总部位于特拉华州及大特拉华谷地区规模最大、经营历史最久的本地管理银行与财富管理机构。集团共运营115个网点，其中88个为银行网点，分布在宾夕法尼亚、特拉华、新泽西、佛罗里达、弗吉尼亚、内华达六州，提供全面金融服务。
CPRX vs WSFS — 直观对比
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $152.6M | $275.3M |
| 净利润 | $52.7M | $86.8M |
| 毛利率 | 82.9% | — |
| 营业利润率 | 40.5% | — |
| 净利率 | 34.5% | 31.5% |
| 营收同比 | 7.6% | 7.5% |
| 净利润同比 | -5.8% | 31.7% |
| 每股收益（稀释后） | $0.40 | $1.64 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q1 26 | — | $275.3M | ||
| Q4 25 | $152.6M | $271.9M | ||
| Q3 25 | $148.4M | $270.5M | ||
| Q2 25 | $146.6M | $267.5M | ||
| Q1 25 | $141.4M | $256.1M | ||
| Q4 24 | $141.8M | $261.5M | ||
| Q3 24 | $128.7M | $267.7M | ||
| Q2 24 | $122.7M | $266.0M |
| Q1 26 | — | $86.8M | ||
| Q4 25 | $52.7M | $72.7M | ||
| Q3 25 | $52.8M | $76.4M | ||
| Q2 25 | $52.1M | $72.3M | ||
| Q1 25 | $56.7M | $65.9M | ||
| Q4 24 | $55.9M | $64.2M | ||
| Q3 24 | $43.9M | $64.4M | ||
| Q2 24 | $40.8M | $69.3M |
| Q1 26 | — | — | ||
| Q4 25 | 82.9% | — | ||
| Q3 25 | 84.7% | — | ||
| Q2 25 | 85.9% | — | ||
| Q1 25 | 87.3% | — | ||
| Q4 24 | 84.7% | — | ||
| Q3 24 | 85.0% | — | ||
| Q2 24 | 87.4% | — |
| Q1 26 | — | — | ||
| Q4 25 | 40.5% | 35.8% | ||
| Q3 25 | 44.7% | 37.3% | ||
| Q2 25 | 45.2% | 35.7% | ||
| Q1 25 | 44.8% | 34.0% | ||
| Q4 24 | 44.3% | 32.3% | ||
| Q3 24 | 39.6% | 31.9% | ||
| Q2 24 | 44.2% | 34.0% |
| Q1 26 | — | 31.5% | ||
| Q4 25 | 34.5% | 26.7% | ||
| Q3 25 | 35.6% | 28.3% | ||
| Q2 25 | 35.6% | 27.0% | ||
| Q1 25 | 40.1% | 25.7% | ||
| Q4 24 | 39.4% | 24.6% | ||
| Q3 24 | 34.1% | 24.1% | ||
| Q2 24 | 33.2% | 26.0% |
| Q1 26 | — | $1.64 | ||
| Q4 25 | $0.40 | $1.33 | ||
| Q3 25 | $0.42 | $1.37 | ||
| Q2 25 | $0.41 | $1.27 | ||
| Q1 25 | $0.45 | $1.12 | ||
| Q4 24 | $0.44 | $1.08 | ||
| Q3 24 | $0.35 | $1.08 | ||
| Q2 24 | $0.33 | $1.16 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $709.2M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $954.3M | $2.7B |
| 总资产 | $1.1B | $22.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q1 26 | — | — | ||
| Q4 25 | $709.2M | $1.7B | ||
| Q3 25 | $689.9M | — | ||
| Q2 25 | $652.8M | — | ||
| Q1 25 | $580.7M | — | ||
| Q4 24 | $517.6M | $1.2B | ||
| Q3 24 | $442.3M | — | ||
| Q2 24 | $375.7M | — |
| Q1 26 | — | $2.7B | ||
| Q4 25 | $954.3M | $2.7B | ||
| Q3 25 | $920.2M | $2.8B | ||
| Q2 25 | $856.0M | $2.7B | ||
| Q1 25 | $794.3M | $2.7B | ||
| Q4 24 | $727.6M | $2.6B | ||
| Q3 24 | $660.9M | $2.7B | ||
| Q2 24 | $608.7M | $2.5B |
| Q1 26 | — | $22.1B | ||
| Q4 25 | $1.1B | $21.3B | ||
| Q3 25 | $1.1B | $20.8B | ||
| Q2 25 | $971.9M | $20.8B | ||
| Q1 25 | $908.9M | $20.5B | ||
| Q4 24 | $851.4M | $20.8B | ||
| Q3 24 | $772.0M | $20.9B | ||
| Q2 24 | $706.4M | $20.7B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $44.9M | — |
| 自由现金流经营现金流 - 资本支出 | $44.9M | — |
| 自由现金流率自由现金流/营收 | 29.4% | — |
| 资本支出强度资本支出/营收 | 0.0% | — |
| 现金转化率经营现金流/净利润 | 0.85× | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
| Q1 26 | — | — | ||
| Q4 25 | $44.9M | $220.0M | ||
| Q3 25 | $32.4M | $121.5M | ||
| Q2 25 | $71.3M | $37.2M | ||
| Q1 25 | $60.0M | $8.7M | ||
| Q4 24 | $70.9M | $219.9M | ||
| Q3 24 | $72.9M | $3.1M | ||
| Q2 24 | $64.1M | $44.8M |
| Q1 26 | — | — | ||
| Q4 25 | $44.9M | $213.6M | ||
| Q3 25 | — | $120.3M | ||
| Q2 25 | $71.3M | $35.2M | ||
| Q1 25 | — | $6.3M | ||
| Q4 24 | $70.8M | $205.6M | ||
| Q3 24 | $72.6M | $-489.0K | ||
| Q2 24 | $64.1M | $42.1M |
| Q1 26 | — | — | ||
| Q4 25 | 29.4% | 78.6% | ||
| Q3 25 | — | 44.5% | ||
| Q2 25 | 48.6% | 13.2% | ||
| Q1 25 | — | 2.5% | ||
| Q4 24 | 49.9% | 78.6% | ||
| Q3 24 | 56.4% | -0.2% | ||
| Q2 24 | 52.3% | 15.8% |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 2.3% | ||
| Q3 25 | 0.0% | 0.5% | ||
| Q2 25 | 0.0% | 0.7% | ||
| Q1 25 | 0.0% | 0.9% | ||
| Q4 24 | 0.1% | 5.5% | ||
| Q3 24 | 0.2% | 1.4% | ||
| Q2 24 | 0.0% | 1.0% |
| Q1 26 | — | — | ||
| Q4 25 | 0.85× | 3.03× | ||
| Q3 25 | 0.61× | 1.59× | ||
| Q2 25 | 1.37× | 0.51× | ||
| Q1 25 | 1.06× | 0.13× | ||
| Q4 24 | 1.27× | 3.43× | ||
| Q3 24 | 1.66× | 0.05× | ||
| Q2 24 | 1.57× | 0.65× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CPRX
| Firdapse | $97.6M | 64% |
| Agamree | $35.3M | 23% |
| Fycompa | $19.6M | 13% |
WSFS
暂无分部数据
